Perspectives on the development of acyclic nucleotide analogs as antiviral drugs

Antiviral Research

Volumn 71, Issue 2-3 SPEC. ISS., 2006, Pages 254-259

  Lee, William A ^a   Martin, John C ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

Acyclic nucleotide analog; Adefovir; Antiviral drug; Intracellular; Nucleotide; Prodrug; Tenofovir

Indexed keywords

9 (3 HYDROXY 2 PHOSPHONOMETHOXYPROPYL)ADENINE; ACICLOVIR; ACYCLIC NUCLEOSIDE; ADEFOVIR; ADEFOVIR DIPIVOXIL; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CARNITINE; CREATININE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GANCICLOVIR; LAMIVUDINE; NUCLEOTIDE DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; PROBENECID; PRODRUG; TENOFOVIR; TENOFOVIR DISOPROXIL; VIRUS RNA;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; BIOACCUMULATION; CELL MEMBRANE PERMEABILITY; CLINICAL TRIAL; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CYTOMEGALOVIRUS; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG SAFETY; EXPERIMENTAL ANIMAL; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; NEPHROTOXICITY; NONHUMAN; PH MEASUREMENT; PHARMACODYNAMICS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RETINITIS; SHORT SURVEY; SYSTEMIC CIRCULATION; SYSTEMIC THERAPY; TISSUE DISTRIBUTION; UNITED STATES;

ADENINE; ANIMALS; ANTIVIRAL AGENTS; DOGS; DRUG DESIGN; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; NUCLEOTIDES; PHOSPHONIC ACIDS; RANDOMIZED CONTROLLED TRIALS;

HEPATITIS B VIRUS;

EID: 33747125380     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.05.020     Document Type: Short Survey

References (36)

1. Balzarini J., Hao Z., Herdewijn P., Johns D.G., and De Clercq E. Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 1499-1503
2. Balzarini J., Holý A., Jindrich J., Naesens L., Snoeck R., Schols D., and De Clercq E. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2, 6-diaminopurine. Antimicrob. Agents Chemother. 37 (1993) 332-338
3. Barditch-Crovo P., Deeks S.G., Collier A., Safrin S., Coakley D.F., Miller M., Kearney B.P., Coleman R.L., Lamy P.D., Kahn J.O., McGowan I., and Lietman P.S. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in HIV-1 infected adults. Antimicrob. Agents Chemother. 45 (2001) 2733-2739
4. Cheng Y.-C., Huang E.-S., Lin J.-C., Mar E.-C., Pagano J.S., Dutschman G.E., and Grill S.P. Unique spectrum of activity of 9-[(1,3-dihydroxy-2-propoxy)methyl]-guanine against herpesviruses in vitro and its mode of action against herpes simplex virus type 1. Proc. Natl. Acad. Sci. U.S.A. 80 (1983) 2767-2770
5. Cherrington J.M., Allen S.J.W., Bischofberger N., and Chen M.S. Kinetic interaction of the diphosphates of 9-(2-phosphonylmethoxyethyl)adenine and other anti-HIV active purine congeners with HIV reverse transcriptase and human DNA polymerases α, b, and g. Antivir. Chem. Chemother. 6 (1995) 217-221
6. Cihlar T., Ray A., Boojamra, D., et al., 2006. GS9148: A novel nucleotide active against HIV-1 variance with drug-resistance mutations in reverse transcriptase. 13th Conference on Retroviruses and Opportunistic Infections, February 5-8, 2006, Denver, CO.
7. Cundy K.C., Barditch-Crovo P., Walker R.E., Collier A.C., Ebeling D., Toole J.J., and Jaffe H.S. Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients. Antimicrob. Agents Chemother. 39 (1995) 2401-2405
8. Cundy K.C., Fishback J.A., Shaw J.-P., Lee M.L., Soike K.F., Visor G.C., and Lee W.A. Oral bioavailability of the antiretroviral agent 9-(2-phosphonylmethoxyethyl)adenine (PMEA) from three formulations of the prodrug bis(pivaloyloxymethyl)-PMEA in fasted male cynomolgus monkeys. Pharm. Res. 11 (1994) 839-843
9. Cundy K.C., Shaw J.-P., and Lee W.A. Oral, subcutaneous, and intramuscular bioavailabilities of the antiviral nucleotide analog 9-(2-phosphonylmethoxyethyl)adenine in cynomolgus monkeys. Antimicrob. Agents Chemother. 38 (1994) 365-368
10. 14C-GS-0840 administered to cynomolgus monkeys. Gilead Sciences Internal Report No. 93-DDM-0840-003.
11. Cundy K.C., Sue I.-L., Visor G.C., Marshburn J., Nakamura C., Lee W.A., and Shaw J.-P. Oral formulations of adefovir dipivoxil: in vitro dissolution and in vivo bioavailability in dogs. J. Pharm. Sci. 86 (1997) 1334-1338
12. De Clercq E., and Holy A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat. Rev. Drug. Discov. 4 (2005) 928-940
13. De Clercq E., Holý A., Rosenberg I., Sakuma T., Balzarini J., and Maudgal P.C. A novel selective broad-spectrum anti-DNA virus agent. Nature 323 (1986) 464-467
14. Deeks S.G., Barditch-Crovo P., Lietman P.S., Hwang F., Cundy K.C., Rooney J.F., Hellmann N.S., Safrin S., and Kahn J.O. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob. Agents Chemother. 42 (1998) 2380-2384
15. Hadziyannis S.J., Tassopoulos N., Heathcote E.J., Chang T.-T., Kitis G., Rizzetto M., Marcellin P., Lim S.G., Goodman Z., Wulfsohn M.S., Xiong S., Fry J., Brosgart C., and The Adefovir Dipivoxil 438 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med. 348 (2003) 800-807
16. Ho E.S., Lin D.C., Mendel D.B., and Cihlar T. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J. Am. Soc. Nephrol. 11 (2000) 383-393
17. Holme E., Jodal U., Linstedt S., and Nordin I. Effects of pivalic acid-containing prodrugs on carnitine homeostasis and on response to fasting in children. Scand. J. Clin. Lab. Invest. 52 (1992) 361-372
18. Holy A. Synthesis of 5'-deoxyuridine 5'-phosphonic acid. Tetrahedron Letters 8 (1967) 881-884
19. Jones G.H., and Moffatt J.G. The synthesis of 6′-deoxyhomonucleoside-6′-phosphonic acids. J. Am. Chem. Soc. 90 (1968) 5337-5338
20. Jung K.-Y., Hohl R.J., Wiemer A.J., and Wiemer D.F. Synthesis of phosphonate derivatives of uridine, cytidine, and cytosine arabinoside. Bioorg. Med. Chem. 8 (2000) 2501-2509
21. Koh Y.-h., Shim J.H., Wu J.Z., Zhong W., Hong Z., and Girardet J.-L. Design, synthesis, and antiviral activity of adenosine 5′-phosphonate analogues as chain terminators against hepatitis C virus. J. Med. Chem. 48 (2005) 2867-2875
22. Lee W., et al. AAC 49 (2005) 1898-1906
23. Mulato A., and Cherrington J. Antiviral Res. 36 (1997) 91-97
24. Marcellin P., Chang T.-T., Lim S.G., Tong M.J., Sievert W., Shiffman M.L., Jeffers L., Goodman Z., Wulfsohn M.S., Xiong S., Fry J., Brosgart C., and The Adefovir Dipivoxil 437 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 348 (2003) 808-816
25. Prisbe E.J., Martin J.C., McGee D.P.C., Barker M.F., Smee D.F., Duke A.E., Matthews T.R., and Verheyden J.P.H. Synthesis and antiherpes virus activity of phosphate and phosphonate derivatives of 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine. J. Med. Chem. 29 (1986) 671-675
26. Robbins B.L., Greenhaw J.J., Connelly M.C., and Fridland A. Metabolic pathways for activation of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine in human lymphoid cells. Antimicrob. Agents Chemother. 39 (1995) 2304-2308
27. Robbins B.L., Srinivas R.V., Kim C., Bischofberger N., and Fridland A. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis(isopropyloxymethylcarbonyl) PMPA. Antimicrob. Agents Chemother. 42 (1998) 612-617
28. Shaw J.-P., and Cundy K.C. Biological screens of PMEA prodrugs. Pharm. Res. 10 (1993) S294
29. Shaw J.-P., Louie M.S., Krishnamurthy V.V., Arimilli M.N., Jones R.J., Bidgood A.M., Lee W.A., and Cundy K.C. Pharmacokinetics and metabolism of selected prodrugs of PMEA in rats. Drug Metab. Dispos. 25 (1997) 362-366
30. Shaw J.-P., Sueoka C.M., Oliyai R., Lee W.A., Arimilli M.N., Kim C.U., and Cundy K.C. Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Pharm. Res. 14 (1997) 1824-1829
31. Srinivas R., et al. Antimicrob. Agents Chemother. 37 (1993) 2247-2250
32. Starrett Jr. J.E., Tortolani D.R., Hitchcock M.J.M., Martin J.C., and Mansuri M.M. Synthesis and in vitro evaluation of a phosphate prodrug: bis(pivaloyloxymethyl)9-(2-phosphonylmethoxyethyl)adenine. Antiviral Res. 19 (1992) 267-273
33. Starrett Jr. J.E., Tortolani D.R., Russell J., Hitchcock M.J.M., Whiterock V., Martin J.C., and Mansuri M.M. Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA). J. Med. Chem. 37 (1994) 1857-1864
34. Tsai C.-C., Follis K.E., Sabo A., Beck T.W., Grant R.F., Bischofberger N., Benveniste R.E., and Black R. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 270 (1995) 1197-1199
35. Van Rompay K.K., Dailey P.J., Tarara R.P., Canfield D.R., Aguirre N.L., Cherrington J.M., Lamy P.D., Bischofberger N., Pedersen N.C., and Marthas M.L. Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn rhesus macaques. J. Virol. 73 (1999) 2947-2955
36. Yengoyan L., and Rammler D.H. Nucleoside phosphonic acids. I. The synthesis of 5′-deoxyuridine 5′-phosphonic acids and derivatives. Biochemistry 5 (1966) 3629-3638